




Ver. 20220401



MEDIPOST

The Future of Biotechnology

Creating a better tomorrow through Innovative Stem Cell Technology



CONTENTS

Company Introduction

About Us & Company Vision	2
CEO Statement	4
Company History	6

Business Introduction

Business Overview	8
Stem Cell Therapeutics	10
Cord Blood Bank – CELLTREE®	14
Nutritional Supplements – MOVITA®	16

Corporate Activity

Global Network	18
Corporate Social Responsibility(CSR)	20

ABOUT US

[KOSDAQ : 078160]

MEDIPOST is an innovative biotechnology company and a global leader in stem cell therapies and regenerative medicine.

<p>R&D-centered Business</p>  <p>49% of the Workforce Allocated to R&D</p>	<p>Advanced Stem Cell Technology</p>  <p>Released the World's First Allogeneic Stem Cell Product</p>	<p>Intellectual Property Rights</p>  <p>Acquired 84 Domestic & International Patents</p>	<p>Korea's Leading Cord Blood Bank, CELLTREE®</p>  <p>No.1 Cord Blood Bank in Korea in Total Cord Blood Stored</p>
---	---	---	---

As of Nov 2021

MEDIPOST aspires to improve the quality of lives for patients with unmet medical needs through rigorous research, development and commercialization in the field of stem cell therapeutics and regenerative medicine.

VISION

Global leader in biotechnology & regenerative medicine with innovative stem cell technologies

MISSION

Providing comprehensive, stem cell-based solutions for health, longevity and improving the quality of lives of patients with unmet medical needs

CORE VALUE

Customer & Patient-Oriented : Care for Lives and Value Creation for customers and patients
Talent-Oriented : Challenging unmet medical needs through Innovation and Passion



CEO STATEMENT

As a global leader in biotechnology with cutting-edge Technologies in Stem Cell Therapeutics, MEDIPOST continues to innovate and challenge to tackle unmet medical needs.

MEDIPOST's mission is to help patients with incurable diseases and unravel unmet medical needs through stem cells and regenerative medicine.

Since its foundation in 2000, MEDIPOST has been making resilient efforts despite difficulties and challenges in the field of stem cell research and commercialization, while upholding strong corporate ethics and values. Today, MEDIPOST is leading the global stem cell therapeutics field with the world's first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee Osteoarthritis(OA), launched in Korean market in 2012.

Biotech industry, including stem cell therapeutics, is deemed to lead the advancement of Korea's innovative future as the next growth-engine industry. MEDIPOST has been awarded with over 33 public R&D grants for commercialization of stem cell therapeutics in Korea and beyond. MEDIPOST holds a very strong sense of responsibility and pride while striving to overcome the boundaries of currently incurable diseases and unmet medical needs both in Korea and abroad, through our R&D efforts in stem cell technology and commercialization.

MEDIPOST aspires to improve the quality of lives for patients with unmet medical needs through rigorous research, development and commercialization in the field of stem cell therapeutics and regenerative medicine while maintaining strong corporate ethics and values.

CEO and President **Yang, Yoon sun**
MEDIPOST Co., Ltd.

COMPANY HISTORY

With patience we have strongly adhered to our ethical standards while making relentless R&D efforts to bring stem cell therapeutics into the market.



2000 – 2005

Launch of CELLTREE®, a cord blood banking service

* CELLTREE®, Korea's No.1 cord blood bank and storage service provider

- Possesses the largest number of cord blood storage units in Korea [Source : 2013.12 the Ministry of Health and Welfare]
- Provides the highest number of cord blood transplants in Korea [Source : the Korea Marrow Donor Program (2015, the Ministry of Health and Welfare)]

* Listed on KOSDAQ (ticker: 078160)

Named as "Best Venture Business in Korea" by the Federation of Korean Industries

Awarded "Bronze Tower" by the Order of Industrial Services Merit



2006 – 2010

Research and Clinical Development of Stem Cell Therapeutics

* Development of allogeneic stem cell therapeutic products derived from human umbilical cord blood.

- Received BLA approval of CARTISTEM® as a treatment of knee cartilage defects in patients with Osteoarthritis(OA) caused by degeneration or repetitive trauma. Ongoing Phase 1/2a clinical trial in the U.S.
- Completed Phase 2 clinical trial of PNEUMOSTEM® as a preventive treatment for Bronchopulmonary Dysplasia (BPD) for premature infants in Korea. Ongoing Phase 1/2 clinical trial in the U.S.
- Completed Phase 1 clinical trial and ongoing Phase 1/2a of NEUROSTEM® for Alzheimer's disease (AD) in Korea.

* The first clinical transplant in Korea using stored umbilical cord blood unit to treat cerebral palsy.

Awarded "Definitive Innovation in Biotechnology" at the Asia Innovation Conference



2011 – Present

Strategy for Growth in Domestic Market & Global Expansion

* Commercial launch of CARTISTEM®, the world's first allogeneic stem cell product, with market approval from MFDS.

* Clinical development in the global market

- Completed clinical trials for CARTISTEM® and PNEUMOSTEM® respectively, in the U.S.
- Orphan drug designation granted for PNEUMOSTEM® in U.S. and EU
- Approval of Phase 2 clinical trial by PMDA & MHLW, Japan

* Next-generation stem cell technology platform

- SMUP-IA-01 (Intra-articular injectable treatment for osteoarthritis) Approved Phase 2 clinical trial in Korea
- SMUP-IV-01 (Intra-venous infusion for treatment of diabetic nephropathy) Scheduled to apply for approval of the domestic clinical trial (Phase 1)

Awarded "Grand Prize" at Korea New Drug Awards



BUSINESS OVERVIEW

MEDIPOST's expertise in stem cell research and development will bring transformational and innovative products to the global market.



Stem Cell Therapeutics

- CARTISTEM®
- PNEUMOSTEM®
- SMUP-IA-01
- SMUP-IV-01



Cord Blood Bank

- CELLTREE®



Nutritional Supplements

- MOVITA®

“The most promising enterprise in the global stem cell industry”

- Strong sales and marketing network centered on umbilical cord blood banking services.
- Around 30% of total annual revenue re-invested on R&D.

84+ Patents
Granted Globally

84+ patents registered and 25+ applied in Korean and worldwide

35 National
Projects
Commissioned

Grantee (Primary Research Organization) of the 'Development of Advanced Global Biopharmaceutical Technologies' by MSIP and MOHW (2015)

Awarded research contract for the Development of Core Technologies for the Bio medical Device Industry by MOTIE (2013)

Grantee (Primary Research Organization) of the 'Consortium for the Commercialization of Stem Cell and Regenerative Medicine' by MOHW (2012)

MEDIPOST Stem Cell Therapeutics

With successful commercialization of the world's first allogeneic stem cell product, MEDIPOST is breaking the barriers in developing treatments for intractable diseases through cutting-edge stem cell technology.



Future of biotechnology and regenerative medicine, the stem cells

Stem cells are undifferentiated cells with the ability to differentiate into various cell types making up the tissues within the body. Stem cells can restore damaged tissues and bodily functions through self-replication, differentiation and/or the secretion of various growth factors.

Healing power of newborn cells, MEDIPOST's cord blood-derived stem cell products

The core strengths of MEDIPOST's stem cell products lies within the most primitive and freshest stem cells derived from umbilical cord blood of the new born babies. Umbilical cord blood is fetal blood found in the umbilical cord of a newborn baby and is the source of the most primitive form of 'adult' stem cells due to the vitality around the time of beginning of life. Umbilical cord blood stem cells are the youngest among all types of adult stem cells and retain the characteristics of stem cells with an excellent regenerative capacity.

Stem Cell Therapeutics Pipeline

Generation	Stem Cell Products	Research	Non-Clinical	IND	Clinical			BLA/Launch
					Phase1	Phase2	Phase3	
1 st Generation Cord Blood-derived Stem Cell Products	CARTISTEM[®] Treatment of knee cartilage defects in patients with Osteoarthritis(OA) due to degeneration or repetitive trauma	Market Approval by MFDS in January 2012						
		Completion of US FDA Phase 1/2a clinical trial			Approval of Phase 2 clinical trial by PMDA & MHLW, Japan			
2 nd Generation Cord Blood-derived Stem Cell Products	PNEUMOSTEM[®] Preventive treatment of bronchopulmonary dysplasia(BPD)	Phase 2 clinical trial is ongoing in Korea						
		Completion of US FDA Phase 1/2 clinical trial						
2 nd Generation Cord Blood-derived Stem Cell Products	SMUP-IA-01 Intra-articular injectable for the treatment of osteoarthritis	Phase 2 clinical trial approved in Korea						
	SMUP-IV-01 Intra-venous infusion for the treatment of diabetic nephropathy	Ongoing non-clinical						

1st Generation Cord Blood-derived Stem Cell Products

MEDIPOST's cutting-edge stem cell technology overcome the limitations on treatment of intractable diseases

CARTISTEM®

Treatment of repetitive and/or traumatic cartilage degeneration including Degenerative Osteoarthritis(OA) without age limit.

January 2012 BLA Approval from MFDS in Korea



CARTISTEM® – allogeneic umbilical cord blood-derived mesenchymal stem cell product, is used for the treatment of knee cartilage defects in patients with Osteoarthritis (with ICRS grade* IV cartilage defect) caused by degeneration or repetitive trauma.

* ICRS grade : A diagnostic criteria used for grading the severity of cartilage defect. Grade IV is the most severe stage with no visible cartilage remaining on the area of defect.

Overseas market expansion

- Completed US FDA Phase 1/2a Clinical Trial
- Approved Japan PMDA & MHLW Phase 2 Clinical Trial

CARTISTEM®



PNEUMOSTEM®

Preventive Treatment of Bronchopulmonary Dysplasia(BPD)

- Phase 2 clinical trial ongoing in Korea
- Completed US FDA Phase 1/2 clinical trial
- Orphan Drug Designation by US FDA & EMA



2nd Generation Cord Blood-derived Stem Cell Products

Next generation cord blood-derived mesenchymal stem cells with higher efficiency and lower cost

SMUP-IA-01

Intra-articular Injectable treatment for osteoarthritis

- Phase 2 clinical trial approved in Korea



SMUP-IV-01

Intra-venous infusion treatment for diabetic nephropathy

- Scheduled to apply for approval of the domestic clinical trial (Phase 1)



SMUP-Cell : Next-generation stem cell technology platform

Advanced Small cell(SM) selection combined with proprietary culture method for retaining and enhancing optimum stem cell characteristics throughout the repeated subculture steps, enable manufacturing of Ultra Potent(UP) cells through large-scale culture expansion.

Next generation cord blood-derived mesenchymal stem cells with higher efficiency and lower cost



Scan the QR code and you will be directed to the page with detailed information.

CELLTREE Cord Blood Bank

Korea's Most-Trusted Cord Blood Bank, CELLTREE®



A 'Treasury' of Stem Cells, the value of Cord Blood

Umbilical cord blood, the fetal blood from the umbilical cord of newborn infants, is rich in both the Hematopoietic Stem Cells (HSCs) which can create all blood components, as well as the Mesenchymal Stem Cells (MSCs) which may develop to become tissues such as cartilage, bones and the muscle. This is why umbilical cord blood is widely recognized as a valuable life-resource that can regenerate damaged tissue functions.

We must strive to preserve human life even if there is a 1% chance of treatment, so let us pursue the value in umbilical cord blood

"Once-in-a-Lifetime Opportunity", the Value of Umbilical Cord Blood Storage.

By taking advantage of the once-in-a-lifetime storage opportunity of umbilical cord blood stem cells which are only available for collection at birth, parents can have their baby's umbilical cord blood stored and made them available at a later date for umbilical cord blood stem cell transplants, if the baby or any family member develops an intractable disease later in life.

There is no need to worry about the loss of a limited time-window for treating intractable diseases due to the difficulty in locating a stem cell donor with histocompatibility. Umbilical cord blood stem cells provide the purest and primitive stem cells which are collected at the moment of birth, which enhances the effectiveness of the treatment. We believe that even with only a 1% chance, the importance of life must be preserved. Thus, we continue to pursue the value of umbilical cord blood.



The first promise for the Healthy Future of My Child

CELLTREE® is a brand name of MEDIPOST's umbilical cord blood bank. MEDIPOST has successfully commercialized the world's first regulatory approved umbilical cord blood-derived mesenchymal stem cell product.

Based on cutting-edge stem cell technology, CELLTREE® boasts its unique expertise and thorough strong know-how on cord blood handling, cell preparation and cryopreservation for the best outcome at the time of transplantation of banked umbilical cord blood-derived stem cells in future.

First-in-Class Technology

CELLTREE®, supported by excellence in storage technology has been proven by numerous transplantations performed on patients with multiple types of disease conditions.

The number of CELLTREE® Transplantations :
559units (As of Nov 2021)

· Unrelated transplantation (465units)


· Autologous-transplantation (78units)

· Related transplantation (16units)

First-in-Class Credibility

CELLTREE®, the umbilical cord blood bank recognized by the largest number of families with the top market-share.

Number of cord blood units stored under CELLTREE® :
270,171units (As of Nov 2021)



Based on data from the Ministry of Health and Welfare Korea (December 2016)

MOVITA Nutritional Supplements

Customized nutritional supplement solution, MOVITA®



First Gift for Your Loved Ones

MOVITA® is MEDIPOST's nutritional supplement brand which provides smart nutritional solutions for the well-being and happiness of everyone in your precious family. MOVITA® provides tailored program to suit the individual's or family's nutritional needs based on customer's age and live-phases with a wide range of products manufactured with only the top-quality ingredients.



MOVITA Pride

Customized programs for special dietary requirements, such as before, during, and after the pregnancy. "Mother's Series" provides a unique combination of nutritional supplements customized for three stages in pregnancy : before, 12th week of pregnancy, and breast-feeding stage.

MOVITA PROMISE

- ① MOVITA® is manufactured with carefully selected ingredients that are proven to be high-quality.
- ② Satisfies Korean Nutritional Standards : MOVITA® is developed based on '2015 Korean People's Nutrition Standards.'



Perfect nutritional supplements for your family

Meets the nutritional needs of everyone in your family, for every gender and age



Dinokiki Probiotics

Contains lactobacillus reuteri derived from breast milk



Gyno-pHresh healthy female probiotics

Vaginal health probiotics that contains two patented Dupont DANISCO's lactobacillus strains and lactoferrin



Hiddink's joint 100

Guus Hiddink's secret for maintaining healthy joints

Balanced nutritional supplement solution throughout pregnancy

Nutritional support which fulfills the needs of both the mother and the unborn baby throughout different stages of pregnancy



Mothers Balance 1step

Essential nutritional supplements for expected mothers



Mothers Balance 2step

Nutritional support for the well-being of the mother and solid growth of the unborn baby throughout the mid-term pregnancy



Mothers Balance 3step

Nutritional support for safe labor during childbirth and healthy breast-feeding

MEDIPOST, a Global Leader in Stem Cell Therapeutics

As a global leader in biotechnology with cutting-edge Technologies in Stem Cell Therapeutics, MEDIPOST continues to innovate and challenge to tackle unmet medical needs.

MEDIPOST GLOBAL MAP

● Overseas Corporation

- MEDIPOST America Inc.
9711 Washingtonian Blvd. Suite 550 Gaithersburg, MD 20878, USA
- EVASTEM Co., Ltd.
Shirokanedai ST Bldg. 7F, 4-7-4 Shirokanedai Minato-ku Tokyo, 108-0071, Japan

○ Patent Right

- U.S.A. / ENGLAND / SWITZERLAND / SINGAPORE
- SPAIN / CHINA / ITALY / CANADA / JAPAN
- AUSTRALIA / FRANCE / HONG KONG / SWEDEN
- NETHERLANDS / INDIA / MEXICO / GERMANY

📍 Partnership

- HONG KONG / MACAO
- MALAYSIA / THAILAND

📍 Cord Blood Transplant

- U.S.A. / CANADA
- SWEDEN / AUSTRALIA

△ Clinical Trial

- U.S.A. / JAPAN





Corporate Social Responsibility(CSR)

Based on our corporate philosophy to respect the value of human lives, MEDIPOST is engaged in sponsorship and charity activities for funding biotechnology research activities for finding cures for the intractable diseases and supporting families in need.

Major Activities

Supporting Storage Cost

Providing sponsorship of cord blood bank services for multi-child families




Supporting Research Fund

Funding basic researches at college of medicine in SNU



Public Cord Blood Bank

Operating cord blood bank which stores over 10,000units



Surgical Sponsorship

Free cord blood transplantation for children with cerebral palsy



Free Cord Blood Storage

Free storage for siblings of children with leukemia



Financial Sponsorship

Sponsoring treatment of underprivileged patients with pediatric cancer and other incurable diseases

